Please assess the completion status of the following clinical trial:

Trial Title: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \>/= 18 years of age with histologically confirmed prostate cancer~* Radiographic evidence of at least one bone metastasis~* Failure of at least one hormonal therapy as evidenced by a rising PSA~* Serum testosterone level of \<50 ng/dL~* ECOG PS 0, 1, or 2~* Adequate organ function~Exclusion Criteria:~* Current or prior IV bisphosphonate administration~* Current or prior oral bisphosphonates for bone mets~* Life expectancy of less than 6 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: ACTIVE_COMPARATOR): None
- denosumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).